Sun Pharma Reports 26% Year-Over-Year Profit Growth to ₹2,714 Crore in Q4 2026, Announces Final Dividend of ₹5 per Share for FY26
Sun Pharma Reports 26.24% YoY Rise in Consolidated Profit for Q4FY26
Sun Pharmaceutical Industries, a leading pharma major, reported a 26.24% year-on-year (YoY) rise in its consolidated profit to ₹2,714.03 crore for the January-March quarter of the financial year 2026 (Q4FY26). This represents a significant increase from the ₹2,149.88 crore profit recorded in the same quarter of the previous financial year.
However, on a sequential or quarter-on-quarter (QoQ) basis, Sun Pharma's consolidated profit fell 19.44%. In Q3FY26, the company's profit was ₹3,368.81 crore. The total revenue from operations for the quarter under review rose 12.8% YoY but fell 5.9% QoQ to ₹14,611.79 crore.
| Q4FY26 | Q3FY26 | Q4FY25 | |
|---|---|---|---|
| Revenue from Operations (₹ crore) | 14,611.79 | 15,520.54 | 12,958.84 |
| YoY Growth | 12.8% | - | - |
| QoQ Growth | -5.9% | - | - |
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
EBITDA for the quarter increased by 6.4% YoY to ₹3,955 crore, but the margin eased to 27.1% from 28.7% YoY. During the quarter, the company's sales stood at ₹14,559.8 crore, clocking a growth of 13.6% YoY.
For the full financial year (FY26), Sun Pharma's net profit increased by 5% to ₹11,479.4 crore, while sales stood at ₹58,220.1 crore, up 11.9% YoY. EBITDA for the year jumped 16.1% YoY to ₹17,731.4 crore, while EBITDA margin rose to 30.3% from 29% YoY.
The company's board has recommended a final dividend of ₹5 per share of ₹1 each, in addition to the interim dividend of ₹11 per share paid in FY26. This takes the total dividend for FY26 to ₹16 per share, the same as FY25.
Sun Pharma said India formulations grew by 14.8%, led by the CVD, CNS, Gastro, and Ortho segments, while US formulations declined marginally to $459 million in Q4FY26. With 14% growth in FY26, India formulations now forms 33% of total consolidated sales. US formulations formed 29% of total consolidated sales in FY26. Emerging markets grew by 13.6% to $1.27 billion in FY26.
Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
Investor Takeaway
Sun Pharma's 26% year-over-year profit growth is a positive sign for the company's financial health.
More in Economy
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
MoSPI Releases Uniform Norms for DDP Estimates with 2022-23 Base Year
